U
TENX icon

UBS’s Tenax Therapeutics TENX Stock Holding History

UBS’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Hold
0
– -$49K – 10753
2014
Q2 		– Hold
0
– – – 6891
2014
Q1 		– Sell
-1
Closed -$198K – 6450
2013
Q4 		$74K Buy
+1
New +$135K ﹤0.01% 6437
2013
Q3 		– Hold
0
– – – 10706
2013
Q2 		– Hold
0
– – – 10193

Other funds holding TENX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

UBS's TENX Position: Q3 2014 in Review

UBS held its Tenax Therapeutics (TENX) position steady in Q3 2014 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #10753.

UBS first reported a position in TENX in Q4 2013 and has held it in 1 quarter since. The position peaked at $74K in Q4 2013. 19 funds tracked by Wall St. Rank hold TENX as of Q3 2014.

  • UBS held 0 shares of Tenax Therapeutics worth $0 as of Q3 2014.
  • UBS left its Tenax Therapeutics share count unchanged in Q3 2014.
  • Tenax Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10753 holding.
  • UBS first reported a position in Tenax Therapeutics in Q4 2013 and has held it in 1 quarter since.
  • UBS's Tenax Therapeutics position peaked at $74K in Q4 2013.
  • 19 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.